The Real BPC-157 Story: 544 Papers, 30 Human Subjects, 50 Million Views

BPC-157 GI and Gut Health

544 Papers Screened

A 2025 systematic review screened 544 BPC-157 articles for orthopaedic applications. Only 1 clinical study met inclusion criteria. Three pilot studies totaling roughly 30 human subjects represent the entire published human evidence base for this peptide.

Vasireddi et al., HSS Journal, 2025

Vasireddi et al., HSS Journal, 2025

View as image

BPC-157 is one of the most discussed peptides on the internet. It has Reddit communities with tens of thousands of members, dedicated podcast segments, and a following that includes professional athletes, biohackers, and parents injecting their children for sports injuries. Search "BPC-157 research" and you will find 544 published papers. What you will not find is anything close to the evidence base those numbers suggest.

A 2025 systematic review in the HSS Journal screened all 544 of those articles for orthopaedic applications.^[1] After applying standard inclusion criteria, 36 studies remained. Thirty-five were animal studies. One was a clinical study in humans. That ratio, 35 to 1, is the real BPC-157 story.

What BPC-157 Actually Is

BPC-157 is a synthetic peptide. It is 15 amino acids long, derived from a larger protein called BPC (Body Protection Compound) that is found in human gastric juice. The key word is "derived." BPC-157 does not exist in this exact 15-amino-acid sequence in the human body. It is a fragment, isolated and synthesized in a lab.

The peptide was first characterized in the early 1990s at the University of Zagreb in Croatia. Researchers there identified it as unusually stable in stomach acid, which is rare for peptides. Most peptides break down within minutes in the acidic environment of the stomach. BPC-157 does not.

In animal studies, BPC-157 appears to work through several pathways. A 2018 review by Sikiric described its effects on the VEGF pathway, which drives the formation of new blood vessels (angiogenesis), and on the nitric oxide system, which regulates blood flow and inflammation.^[7] A 2014 study by Chang and colleagues in Taiwan found that BPC-157 increased growth hormone receptor expression in tendon fibroblasts, cells that build and repair tendons.^[9] That Taiwanese study is notable because it is one of the few BPC-157 mechanism studies conducted outside the originating lab in Zagreb. For more on oral BPC-157 and its gastric stability, that topic gets its own deep dive.

The 544-Paper Illusion

The number 544 sounds impressive. It is meant to. But what does that number actually contain?

Vasireddi and colleagues at the Hospital for Special Surgery published the most rigorous accounting of BPC-157 literature to date in 2025.^[1] They screened 544 articles published between 1993 and 2024. After removing duplicates, reviews, editorials, and studies that did not meet basic methodological standards, 36 remained. Of those 36, 35 were preclinical studies conducted in animals. One was a clinical study.

That is a 99.7% animal-to-human ratio.

A separate 2025 narrative review by McGuire and colleagues asked a blunter question in its title: "Regeneration or Risk?"^[2] Their conclusion: the preclinical evidence is consistently positive, but the absence of human data makes it impossible to generate evidence-based practice guidelines. The gap between what BPC-157 does in a rat and what it does in a human is not a small gap. In pharmaceutical development, roughly 90% of drugs that work in animals fail in human trials. BPC-157 has not yet reached the point where it can fail, because the trials have not been conducted.

Every Human Study, Counted

Three studies. One author. One journal. Roughly 30 total subjects.

Study 1: Knee pain (2021). Edwin Lee published a pilot study of intra-articular BPC-157 injections for chronic knee pain in Alternative Therapies in Health and Medicine.^[4] Twelve patients received a single injection. Seven reported pain relief lasting more than six months. There was no control group, no placebo arm, no blinding. The patients knew what they were receiving, and the outcomes were self-reported.

Study 2: Interstitial cystitis (2024). Lee published a second pilot, this time for interstitial cystitis (chronic bladder pain), in the same journal.^[5] Interstitial cystitis is a condition with few effective treatments, which makes any positive signal interesting. But the study had a small sample, no control group, and self-reported symptom outcomes. Without a placebo arm, there is no way to separate the effect of BPC-157 from the natural fluctuation of a condition known for symptom waxing and waning.

Study 3: IV safety (2025). Lee's third study tested intravenous BPC-157 infusion in 2 healthy adults at doses up to 20 mg.^[3] No adverse events were reported. The study's purpose was safety, not efficacy, and with 2 subjects it can establish only that those 2 specific people tolerated the infusion.

All three studies appear in Alternative Therapies in Health and Medicine, a journal that does not carry the same peer review rigor as major medical journals. All three are by the same author. None have been independently replicated. None are randomized controlled trials.

For context, semaglutide (Ozempic) went through Phase III trials involving thousands of patients across multiple countries before approval. BPC-157 has 30 subjects, one investigator, and no Phase III trial on any horizon. A deeper look at why there is almost no human data is covered separately.

The Single-Lab Problem

Predrag Sikiric is a professor of pharmacology at the University of Zagreb. His lab has produced more than 150 published papers on BPC-157 since 1993. By any measure, the majority of the entire BPC-157 literature comes from this one group.

In science, a finding is not considered established until it has been independently replicated, meaning a different lab with different researchers, different equipment, and no financial connection to the original team gets the same result. For BPC-157, that independent replication is nearly absent.

There are exceptions. Chang and colleagues in Taiwan showed in 2014 that BPC-157 upregulated growth hormone receptor expression in tendon fibroblasts.^[9] Xu and colleagues in China conducted a formal preclinical safety evaluation in 2020, testing BPC-157 for acute toxicity, genotoxicity, and hemolysis in rats.^[8] They found no acute toxicity at doses up to 10 mg/kg. These independent studies exist. But they are the exception, not the pattern.

There is a further complication. Sikiric is listed as the CEO of a company called Diagen, which holds patents for what it describes as a "special stable version" of BPC-157. This financial interest was not disclosed in his published papers. In standard scientific practice, a researcher with a patent and a company tied to their research subject would be required to declare that conflict. The full scope of this single-lab concentration is worth its own examination.

The Ghost Trial

In the late 1990s and early 2000s, the Croatian pharmaceutical company Pliva sponsored clinical trials for BPC-157 as a treatment for inflammatory bowel disease. The peptide was assigned three drug designations: PL-10, PLD-116, and PL14736.

Sikiric described the program in a 2006 review in Inflammopharmacology.^[6] Phase I trials tested rectal administration of BPC-157 in healthy volunteers and found it safe and well-tolerated. A Phase II trial in patients with mild-to-moderate ulcerative colitis was initiated.

Then nothing happened. Or more precisely, nothing was ever made public.

The Phase II results were never published. No journal article, no conference abstract, no press release. A clinical trial registration (NCT02637284) appears on ClinicalTrials.gov with a status listed as unknown since 2016. The trial was supposed to report results. It did not. Pliva was acquired by Barr Pharmaceuticals, which was later acquired by Teva Pharmaceutical Industries. Whether the trial data exists inside Teva's archives, whether the results were negative, or whether the trial simply stopped when the company changed hands is not publicly known.

This is what is known as a ghost trial: a study that was registered, conducted, and then never reported. Ghost trials are a recognized problem in clinical research because negative results that go unpublished distort the evidence base. If BPC-157 failed in the one controlled human trial that was actually conducted, that failure is invisible. For a deeper look at this specific topic, see BPC-157 for inflammatory bowel disease.

What the Animal Studies Actually Show

The preclinical evidence for BPC-157 is not fabricated or trivial. Across more than 100 animal studies, BPC-157 has shown consistent effects in specific domains.

The most-cited musculoskeletal study is Staresinic et al. (2003), which tested BPC-157 on transected rat Achilles tendons.^[10] Rats that received BPC-157 showed accelerated tendon healing compared to controls, along with increased tendocyte growth in vitro. This study has been replicated in variations (different tendons, different injury models) primarily within the Zagreb lab.

Gastric protection is where BPC-157 was first identified. Dozens of studies show it protects rat stomach lining against NSAIDs, alcohol, and stress-induced ulcers. The effect is consistent enough that BPC-157's discoverers named it "Body Protection Compound" specifically for this property.

Fistula healing is another area with multiple positive animal studies. BPC-157 has been tested on gastrocutaneous, rectovaginal, colovesical, and esophagocutaneous fistulas in rats, with positive results in each model.

But three things limit what these animal studies can tell us.

First, the route of administration. Most rat studies use intraperitoneal injection (directly into the abdominal cavity). That is not how people use BPC-157. Subcutaneous injection and oral capsules, the two most common human routes, have not been studied with the same rigor in animals.

Second, the doses. Animal doses are calculated per kilogram of body weight and do not scale linearly to humans. The "effective dose" in a 250-gram rat does not translate directly to a dose for an 80-kilogram human.

Third, the translation rate. Drug development has a well-documented failure rate: roughly 90% of compounds that show promise in animal models fail in human trials. This is not a BPC-157-specific problem. It is a fundamental limitation of preclinical research. BPC-157 for tendon injuries covers the musculoskeletal animal data in detail.

The Regulatory and Legal Reality

In 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance. Category 2 means the FDA has determined that the substance "may present significant safety risks" when used in compounding. Licensed pharmacies cannot legally compound BPC-157 for human use.

The FDA cited three concerns: potential immunogenicity (the peptide could trigger immune reactions), manufacturing impurity risks (synthetic peptides can contain truncated sequences and other contaminants), and a lack of human safety data sufficient to evaluate risk.

BPC-157 also appears on WADA's prohibited list. Athletes who test positive for BPC-157 face sanctions. The anti-doping agency USADA has issued specific warnings about BPC-157, calling it an "experimental peptide" with insufficient safety data.

No regulatory agency anywhere in the world has approved BPC-157 for any indication.

The peptide remains available through "research peptide" suppliers who sell it labeled as "not for human consumption." This legal gray area allows it to be purchased without a prescription, compounding the safety concern: the purity, sterility, and actual contents of these products are not guaranteed by any regulatory body. For a full breakdown of the regulatory landscape, see BPC-157 and the FDA's Category 2 classification.

Where This Leaves the Evidence

BPC-157 is not a scam. The animal data is real, extensive, and consistently positive across multiple injury and disease models. Something is happening in those rat studies. The peptide has biological activity.

But the human evidence is thinner than for almost any substance with this level of internet popularity. Three pilot studies. One investigator. Roughly 30 subjects. No randomized controlled trial. No Phase III data. No published results from the one Phase II trial that was actually conducted.

The gap between what people believe about BPC-157 and what has been demonstrated in humans is one of the largest in peptide research. That gap is not closing. No major pharmaceutical company is running BPC-157 trials. The FDA's Category 2 classification makes clinical development in the United States more difficult, not less. And the single-lab concentration of the existing evidence means that what we have is not what scientists would call a robust, independently verified evidence base.

None of this means BPC-157 will never work in humans. It means we do not yet know whether it does. And the infrastructure that would normally answer that question, large pharmaceutical trials with thousands of patients and independent oversight, does not exist for this compound and shows no signs of materializing.

The internet has made its decision about BPC-157. The science has not.

The Bottom Line

BPC-157 has real preclinical data across dozens of animal models showing consistent healing effects. What it does not have is meaningful human evidence. Three pilot studies, one investigator, roughly 30 subjects, and no randomized controlled trial. The gap between the internet narrative and the published science is one of the largest in peptide research.

Frequently Asked Questions

Does BPC-157 actually work?

In animals, yes. Over 100 rat and mouse studies show accelerated healing in tendons, gastric ulcers, fistulas, and other injury models. In humans, we do not know. Only about 30 people have been studied across 3 small pilot studies, none of which included a control group or blinding. The animal results are consistent, but roughly 90% of drugs that work in animals fail when tested in people.

How many human studies exist for BPC-157?

Three. All were published by Edwin Lee in Alternative Therapies in Health and Medicine. The first (2021) tested knee injections in 12 patients. The second (2024) tested it for interstitial cystitis. The third (2025) tested IV safety in 2 healthy adults. No randomized controlled trials exist.

Why did the FDA ban BPC-157?

The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, meaning it cannot be legally compounded by pharmacies. The FDA cited three concerns: potential immune reactions, manufacturing impurity risks, and insufficient human safety data. BPC-157 has no approved indication in any country.

Is BPC-157 safe for humans?

The only formal safety study was conducted in rats (Xu et al., 2020), which found no acute toxicity at doses up to 10 mg/kg. In humans, 2 subjects tolerated IV infusion up to 20 mg without adverse events (Lee, 2025). That is the full extent of published human safety data. Products sold as "research peptides" are not regulated for purity or sterility.

Who does most BPC-157 research?

Predrag Sikiric's lab at the University of Zagreb has published over 150 of the approximately 544 papers on BPC-157. Sikiric is also CEO of Diagen, a company that holds BPC-157 patents. This conflict of interest was not disclosed in his published studies. Independent replication from other labs exists but is rare.

Was there ever a BPC-157 clinical trial for IBD?

Yes. Croatian pharmaceutical company Pliva sponsored Phase I and Phase II trials for BPC-157 in inflammatory bowel disease in the early 2000s. Phase I found it safe in healthy volunteers. Phase II for ulcerative colitis was initiated but results were never published. The trial registration on ClinicalTrials.gov has been listed as "unknown status" since 2016.